drugset
Drugs / EDRALBRUTINIB
last change Dec 2024 re-read 2 minutes ago

EDRALBRUTINIB

also known as SHR1459 · TG-1701

Small molecule targets BTK via inhibition

Developed for
B-cell non-Hodgkin lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · neoplasm of mature B-cells · neuromyelitis optica · idiopathic membranous glomerulonephritis
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Reistone Biopharma Company Limited · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · TG Therapeutics, Inc.

Trials 11 · a red edge is where a trial was stopped

today NCT05560360 · Ph 1 NCT05095337 · Ph 1 NCT04948788 · Ph 2 NCT04670770 · Ph 2 NCT04649723 · Ph 1 NCT04455100 · Ph 1 NCT04395053 · Ph 1 NCT04291846 · Ph 1 NCT03671590 · Ph 1 NCT03668509 · Ph 1 NCT03664297 · Ph 1
201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT05560360 Nov → Dec 2022 B-cell neoplasm Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT05095337 Jun → Jul 2022 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04649723 Nov → Dec 2020 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04455100 Jul → Aug 2020 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04395053 Jun → Jul 2020 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04291846 May → Jun 2020 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT03671590 Sep 2018 → May 2024 chronic lymphocytic leukemia/small lymphocytic lymphoma TG Therapeutics, Inc. Terminated No outcome recorded
Phase 1 NCT03668509 Sep 2018 → Jan 2019 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT03664297 Feb 2018 → Dec 2023 neoplasm of mature B-cells Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 22 trials
Phase 2 NCT04948788 Oct 2021 → Apr 2023 B-cell non-Hodgkin lymphoma Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 2 NCT04670770 Jan 2021 → Aug 2022 neuromyelitis optica Reistone Biopharma Company Limited Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05136456 Comparator Dec 2021 → Aug 2023 idiopathic membranous glomerulonephritis Reistone Biopharma Company Limited Unknown No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as EDRALBRUTINIB ChEMBL registry synonym — accepted as the source's own label CHEMBL4650338 ↗
Known as SHR1459 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03664297 ↗
10

NCT04670770 ↗

NCT04291846 ↗

NCT05560360 ↗

NCT05095337 ↗

NCT04455100 ↗

NCT04948788 ↗

NCT05136456 ↗

NCT03668509 ↗

NCT04395053 ↗

NCT04649723 ↗
Known as TG-1701 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03671590 ↗
Action Inhibit “by inhibiting the phosphorylation of BTK” NCT03664297 ↗
Modality Small molecule “SHR1459 is a selective small molecule BTK inhibitor” NCT03664297 ↗
Route Oral “oral adminstration of SHR1459, dose 1” NCT03668509 ↗
Target BTK “by inhibiting the phosphorylation of BTK” NCT03664297 ↗